QiJia Biotech Completes Tens of Millions RMB in Angel Funding to Build a World-Leading iPSC-Based Humanized Biomimetic Micro-Organ R&D Platform

VCBeat has learned at the earliest opportunity,Qijia Technology (Suzhou) Co., Ltd.(Abbreviation:Qijia Technology) has recently officially completed an angel financing round worth tens of millions of RMB. This round of financing was led byiFlytek VenturesSole Lead Investor,ROBE CAPITALServing as the exclusive financial advisor. The funds raised will be used for the construction and commercial translation of the human bionic micro-organ technology platform.

As a precision tool for next-generation preclinical drug development, organoids have gradually gained recognition from the global industry and academia. They hold promise for addressing core pain points in the drug R&D process, such as significant predictive deviations in animal models, low screening efficiency (high costs), and the difficulty or impossibility of modeling numerous indications. However, mainstream organoid technologies remain largely confined to 2D cell models or 2D/3D co-culture systems. Their insufficient biomimicry under physiological conditions, and consequently limited clinical relevance under pathological conditions, fundamentally restrict their potential for large-scale application, failing to truly meet the needs of pharmaceutical companies and scientific researchers.

Qijia Tech was founded in 2022 by Dr. Ge Xiaohu, who co-established the company with Dr. Wu Di and Mr. Wan Fei. It is a biomimetic micro-organ platform company. With the mission of “developing more realistic micro-organs to serve human health,” Qijia Tech is committed to addressing industry pain points such as the inadequacy of preclinical drug evaluation models and the low efficiency of organoid-based regenerative repair.

With its internationally pioneeringiPS Lineage Co-differentiation TechnologyQijia Technology has achieved a comprehensive expansion of traditional organoid models in terms of lineage, structure, and function, revolutionarily bringing next-generation humanized 3D biomimetic micro-organs to market, and providing systematic solutions for three application scenarios: scientific research, drug development, and precision medicine.

Currently, the Qijia Science teamDevelopment of Human-Derived Biomimetic Micro-Organ Systems for the Respiratory and Digestive Tracts Completed, availableStandardized Products of Human-Derived Biomimetic Micro-Organs (Lung/Liver/Pancreas/Duodenum/Colorectum, etc.) (Kits, Upstream and Downstream Reagents, Mature Micro-Organs)andCustomized ServiceTask。

The company has been granted nearly 20 invention patents, achieving proprietary intellectual property coverage across the entire technology chain, and has undertaken multiple national, provincial, and ministerial-level research projects. In the future, as Qijia Technology continues to expand its product and service portfolio, it will advance standardization, high-throughput capabilities, and automation to comprehensively empower drug development and academic research.

Dr. Wu Di, CEO of Qijia TechnologyStatement: We extend our gratitude to iFlytek Ventures for their trust and support. Leveraging our core advantage in organ biomimicry, Qijia Technology will accelerate the development of a standardized system for iPSC-derived micro-organs, further expand the variety of physiological and pathological systems, and deepen our penetration into research and industrial markets. By employing next-generation biomimetic organ models, we aim to facilitate advanced life sciences research and drive the rapid growth of the pharmaceutical industry.

NewsDr. Ding Jingna, Investment Director and Head of the Healthcare Group at ROBE CAPITALStatement: iFlytek Ventures continues to strategically invest in the healthcare sector, recognizing the significant potential of the organoid industry in accelerating new drug development and anticipating future integration with artificial intelligence technologies. Qijia Technology’s iPSC multi-lineage co-differentiation technology can induce the differentiation of various types of micro-organs with high biomimetic fidelity, directly addressing current pain points in life sciences research. Furthermore, preclinical studies based on organoids can guide more precise clinical drug regimens, helping pharmaceutical companies shorten clinical trial cycles and improve clinical success rates. We believe that, leveraging its core technological advantages and standardized product solutions, Qijia Technology can serve as a catalyst for accelerating drug development and life sciences research, driving the industry into a new era.

Hu Yubing, Partner at ROBE CAPITALIt was stated that the organoid industry, as a high-growth sector, has long attracted significant attention. However, the industry remains concerned about the limitations of past organoid technologies and their resulting application scenarios. Key questions include: Are organoids only applicable to diseases that cannot be modeled? Is the spectrum of differentiated cell lineages comprehensive and sufficiently biomimetic? How can the issue of traditional physical stacking techniques failing to recapitulate intercellular signaling pathways be addressed? And how can organoids be applied in industrial settings with high throughput and low cost? In response to these challenges, we have identified solutions within the Qijia team. Leveraging its globally pioneering differentiation technology, robust patent protection, and systematic product portfolio layout, Qijia has established a unique and competitive business model. We believe that Qijia Technology’s product positioning, grounded in industrial needs, will become a revolutionary breakthrough in next-generation drug development.

iFlytek Ventures is a leading venture capital platform dedicated to artificial intelligence and its related applications, adhering to the investment philosophy of “industry + technology + capital.” Leveraging iFlytek’s industrial expertise and resource integration capabilities, iFlytek Ventures has established extensive investments in early-stage hard technology and healthcare sectors, pursuing enabling industrial ecosystem investments. By coordinating resources across technology, industry, and capital, it helps enhance the value of its portfolio companies.

ROBE CAPITAL, established in 2017, is a boutique investment bank specializing in healthcare and life sciences. Its business portfolio encompasses financial advisory, direct investment, industry consulting, and innovation incubation. The founding team hails from leading private equity firms, financial advisory institutions, management consulting companies, and vertical healthcare media outlets. Since its inception, ROBE CAPITAL has consistently completed double-digit private financing and M&A transactions annually, with a cumulative transaction value exceeding RMB 10 billion. The firm’s team also brings extensive industry expertise to corporate value-added services. In 2020, the ROBE New Healthcare Fund was launched and has since invested in multiple leading companies within the sector.